133 related articles for article (PubMed ID: 18224669)
21. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
Macaulay VM; O'Byrne KJ; Saunders MP; Braybrooke JP; Long L; Gleeson F; Mason CS; Harris AL; Brown P; Talbot DC
Clin Cancer Res; 1999 Mar; 5(3):513-20. PubMed ID: 10100701
[TBL] [Abstract][Full Text] [Related]
22. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.
Mundt AJ; Vijayakumar S; Nemunaitis J; Sandler A; Schwartz H; Hanna N; Peabody T; Senzer N; Chu K; Rasmussen CS; Kessler PD; Rasmussen HS; Warso M; Kufe DW; Gupta TD; Weichselbaum RR
Clin Cancer Res; 2004 Sep; 10(17):5747-53. PubMed ID: 15355902
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study.
Krown SE; Li P; Von Roenn JH; Paredes J; Huang J; Testa MA
J Interferon Cytokine Res; 2002 Mar; 22(3):295-303. PubMed ID: 12034036
[TBL] [Abstract][Full Text] [Related]
24. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
[TBL] [Abstract][Full Text] [Related]
26. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
27. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.
Bower M; Weir J; Francis N; Newsom-Davis T; Powles S; Crook T; Boffito M; Gazzard B; Nelson M
AIDS; 2009 Aug; 23(13):1701-6. PubMed ID: 19550283
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma.
Pantanowitz L; Dezube BJ; Hernandez-Barrantes S; Tahan SR; Dabbous MK
J Cutan Pathol; 2006 Dec; 33(12):793-8. PubMed ID: 17177939
[TBL] [Abstract][Full Text] [Related]
29. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases.
Brambilla L; Romanelli A; Bellinvia M; Ferrucci S; Vinci M; Boneschi V; Miedico A; Tedeschi L
Br J Dermatol; 2008 Jun; 158(6):1339-44. PubMed ID: 18363766
[TBL] [Abstract][Full Text] [Related]
30. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
31. Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science.
Dezube BJ; Sullivan R; Koon HB
J Cell Physiol; 2006 Dec; 209(3):659-62. PubMed ID: 17001705
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
34. KS trial begins.
AIDS Patient Care STDS; 2000 Jun; 14(6):338. PubMed ID: 10897507
[No Abstract] [Full Text] [Related]
35. A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.
Gharibo M; Patrick-Miller L; Zheng L; Guensch L; Juvidian P; Poplin E
Pancreas; 2008 May; 36(4):341-5. PubMed ID: 18437079
[TBL] [Abstract][Full Text] [Related]
36. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
Grossman SA; Carson KA; Batchelor TT; Lesser G; Mikkelsen T; Alavi JB; Phuphanich S; Hammour T; Fisher JD; Supko JG
Clin Cancer Res; 2006 Sep; 12(17):5174-81. PubMed ID: 16951236
[TBL] [Abstract][Full Text] [Related]
37. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
38. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
[TBL] [Abstract][Full Text] [Related]
39. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
Hotte SJ; Hirte HW; Chen EX; Siu LL; Le LH; Corey A; Iacobucci A; MacLean M; Lo L; Fox NL; Oza AM
Clin Cancer Res; 2008 Jun; 14(11):3450-5. PubMed ID: 18519776
[TBL] [Abstract][Full Text] [Related]
40. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
